<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>IUIS classification of bone marrow failure (category IX inborn errors of immunity)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">IUIS classification of bone marrow failure (category IX inborn errors of immunity)</h1>
<div class="graphic"><div class="figure"><div class="ttl">IUIS classification of bone marrow failure (category IX inborn errors of immunity)</div><div class="cntnt"><table cellspacing="0"><colgroup span="8" width="12.5%"></colgroup> <tbody> <tr> <td class="subtitle1">Disease</td> <td class="subtitle1">Genetic defect</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">OMIM</td> <td class="subtitle1">T cells</td> <td class="subtitle1">B cells</td> <td class="subtitle1">Other affected cells</td> <td class="subtitle1">Associated features</td> </tr> <tr> <td>Fanconi anemia type A</td> <td>FA complementation group A (<em>FANCA</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/227650" target="_blank">227650</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type B</td> <td>FA complementation group B (<em>FANCB</em>)</td> <td>XLR</td> <td><a href="https://www.omim.org/entry/300514" target="_blank">300514</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type C</td> <td>FA complementation group C (<em>FANCC</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/227645" target="_blank">227645</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type D1</td> <td>BRCA2 DNA repair associated (<em>BRCA2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/605724" target="_blank">605724</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type D2</td> <td>FA complementation group D2 (<em>FANCD2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/227646" target="_blank">227646</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type E</td> <td>FA complementation group E (<em>FANCE</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/600901" target="_blank">600901</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type F</td> <td>FA complementation group F (<em>FANCF</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/603467" target="_blank">603467</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type G</td> <td>FA complementation group G (<em>FANCG</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/614082" target="_blank">614082</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type I</td> <td>FA complementation group I (<em>FANCI</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/609053" target="_blank">609053</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type J</td> <td>BRCA1-interacting helicase 1 (<em>BRIP1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/609054" target="_blank">609054</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type L</td> <td>FA complementation group L (<em>FANCL</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/614083" target="_blank">614083</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type M</td> <td>FA complementation group M (<em>FANCM</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/618096" target="_blank">618096</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type N</td> <td>Partner and localizer of BRCA2 (<em>PALB2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/610832" target="_blank">610832</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type O</td> <td>RAD51 paralog C (<em>RAD51C</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/613390" target="_blank">613390</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type P</td> <td>SLX4 structure-specific endonuclease subunit (<em>SLX4</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/613951" target="_blank">613951</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type Q</td> <td>ERCC excision repair 4, endonuclease catalytic subunit (<em>ERCC4</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/615272" target="_blank">615272</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type R</td> <td>RAD51 recombinase (<em>RD51</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/617244" target="_blank">617244</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type S</td> <td>BRCA1 DNA repair associated (<em>BRCA1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/617883" target="_blank">617883</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type T</td> <td>Ubiquitin-conjugating enzyme E2 T (<em>UBE2T</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/616435" target="_blank">616435</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type U</td> <td>X-ray repair cross complementing 2 (<em>XRCC2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/617247" target="_blank">617247</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type V</td> <td>Mitotic arrest-deficient 2-like 2 (<em>MAD2L2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/617243" target="_blank">617243</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>Fanconi anemia type W</td> <td>Ring finger and WD repeat domain 3 (<em>RFWD3</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/617784" target="_blank">617784</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Normal to low NK cells; CNS, skeletal, skin, cardiac, GI, and urogenital anomalies; increased chromosomal breakage</td> </tr> <tr> <td>MIRAGE (myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, enteropathy)</td> <td>Sterile alpha motif domain-containing 9 (<em>SAMD9</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/617053" target="_blank">617053</a></td> <td>Not reported</td> <td>Not reported</td> <td>HSCs, myeloid cells</td> <td>Intrauterine growth retardation, gonadal abnormalities, adrenal failure, MDS with chromosome 7 aberrations, predisposition to infections, enteropathy, absent spleen</td> </tr> <tr> <td>Ataxia pancytopenia syndrome</td> <td>Sterile alpha motif domain-containing 9-like (<em>SAMD9L</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/611170" target="_blank">611170</a></td> <td>Normal</td> <td>Low</td> <td>HSCs, myeloid cells</td> <td>MDS, neurologic features</td> </tr> <tr> <td>Dyskeratosis congenita, XL (DKCX1)</td> <td>Dyskerin pseudouridine synthase 1 (<em>DKC1</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/305000" target="_blank">305000</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation, microcephaly, neurodevelopmental delay</td> </tr> <tr> <td>Dyskeratosis congenita, AD 1 (DKCA1)</td> <td>Telomerase RNA component (<em>TERC</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/127550" target="_blank">127550</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation, microcephaly, neurodevelopmental delay</td> </tr> <tr> <td>Dyskeratosis congenita, AD 2 (DKCA2)</td> <td>Telomerase reverse transcriptase (<em>TERT</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/187270" target="_blank">187270</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation, microcephaly, neurodevelopmental delay</td> </tr> <tr> <td>Dyskeratosis congenita, AD 3 (DKCA3)</td> <td>TERF1-interacting nuclear factor 2 (<em>TINF2</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/604319" target="_blank">604319</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation, microcephaly, neurodevelopmental delay</td> </tr> <tr> <td>Dyskeratosis congenita, AD 4 (DKCA4)</td> <td>Regulator of telomere elongation helicase 1 (<em>RTEL1</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/616373" target="_blank">616373</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation, microcephaly, neurodevelopmental delay</td> </tr> <tr> <td>Dyskeratosis congenita, AD 5 (DKCA5)</td> <td>TERF1-interacting nuclear factor 2 (<em>TINF2</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/268130" target="_blank">268130</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation, microcephaly, neurodevelopmental delay</td> </tr> <tr> <td>Dyskeratosis congenita, AD 6 (DKCA6)</td> <td>ACD shelterin complex subunit and telomerase recruitment factor (<em>ACD</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/616553" target="_blank">616553</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation, microcephaly, neurodevelopmental delay</td> </tr> <tr> <td>Dyskeratosis congenita, AR 1 (DKCB1)</td> <td>NOP10 ribonucleoprotein (<em>NOP10</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/224230" target="_blank">224230</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation, microcephaly, neurodevelopmental delay</td> </tr> <tr> <td>Dyskeratosis congenita, AR 2 (DKCB2)</td> <td>NHP2 ribonucleoprotein (<em>NHP2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/613987" target="_blank">613987</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation, microcephaly, neurodevelopmental delay</td> </tr> <tr> <td>Dyskeratosis congenita, AR 3 (DKCB3)</td> <td>WD repeat-containing antisense to TP53 (<em>WRAP53</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/613988" target="_blank">613988</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation, microcephaly, neurodevelopmental delay</td> </tr> <tr> <td>Dyskeratosis congenita, AR 4 (DKCB4)</td> <td>Telomerase reverse transcriptase (<em>TERT</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/613989" target="_blank">613989</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation, microcephaly, neurodevelopmental delay</td> </tr> <tr> <td>Dyskeratosis congenita, AR 5 (DKCB5)</td> <td>Regulator of telomere elongation helicase 1 (<em>RTEL1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/615190" target="_blank">615190</a></td> <td>Normal to low</td> <td>Low</td> <td>HSCs</td> <td>Nail dystrophy, leukoplakia, bone marrow failure, severe B cell immunodeficiency, intrauterine growth retardation, growth retardation, microcephaly, cerebellar hypoplasia, esophageal dysfunction</td> </tr> <tr> <td>Dyskeratosis congenita, AR 6 (DKCB6)</td> <td>Poly(A)-specific ribonuclease (<em>PARN</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/616353" target="_blank">616353</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Developmental delay, microcephaly, cerebellar hypoplasia</td> </tr> <tr> <td>Dyskeratosis congenita, AR 7 (DKCB7)</td> <td>ACD shelterin complex subunit and telomerase recruitment factor (<em>ACD</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/616553" target="_blank">616553</a></td> <td>Normal to low</td> <td>Normal to low</td> <td>HSCs</td> <td>Bone marrow failure, pulmonary and hepatic fibrosis, nail dystrophy, leukoplakia, reticulate skin pigmentation, microcephaly, neurodevelopmental delay</td> </tr> <tr> <td>Bone marrow failure syndrome 1 (BMFS1; SRP72 deficiency</td> <td>Signal recognition particle 72 (<em>SRP72</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/602122" target="_blank">602122</a></td> <td>Not applicable</td> <td>Not applicable</td> <td> </td> <td>Bone marrow failure and congenital nerve deafness</td> </tr> <tr> <td>Bone marrow failure syndrome 2 (BMFS2)</td> <td>ERCC excision repair 6-like 2 (<em>ERCC6L2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/615667" target="_blank">615667</a></td> <td>Not applicable</td> <td>Not applicable</td> <td> </td> <td>Bone marrow failure, learning difficulties, microcephaly</td> </tr> <tr> <td>Bone marrow failure syndrome 5 (BMFS5)</td> <td>Tumor protein p53 (<em>TP53</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/618165" target="_blank">618165</a></td> <td>Not applicable</td> <td>Low B cells</td> <td> </td> <td>Erythroid hypoplasia, B cell deficiency</td> </tr> <tr> <td rowspan="2">Coats plus syndrome</td> <td>STN1 subunit of CST complex (<em>STN1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/613128" target="_blank">613128</a></td> <td>Normal</td> <td>Normal</td> <td> </td> <td>Intrauterine growth retardation, premature aging, pancytopenia, hypocellular bone marrow, GI hemorrhage due to vascular ectasia, intracranial calcification, abnormal telomeres</td> </tr> <tr> <td>CST telomere replication complex component 1 (<em>CTC1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/613129" target="_blank">613129</a></td> <td>Not reported</td> <td>Not reported</td> <td> </td> <td>Intrauterine growth retardation, premature aging, pancytopenia, hypocellular bone marrow, GI hemorrhage due to vascular ectasia, intracranial calcification, abnormal telomeres</td> </tr> <tr> <td>MECOM deficiency</td> <td>MDS1 and EVI1 complex locus (<em>MECOM</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/616738" target="_blank">616738</a></td> <td>Not reported</td> <td>B cell deficiency</td> <td> </td> <td>Bone marrow failure, thrombocytopenia/pancytopenia, radioulnar synostosis, clinodactyly, cardiac and renal malformations</td> </tr> </tbody></table></div><div class="graphic_lgnd">Total number of mutant genes in table: 44.</div><div class="graphic_footnotes">IUIS: International Union of Immunological Societies; 
    AR: autosomal recessive; 
    HSC: hematopoietic stem cell; 
    NK: natural killer; 
    CNS: central nervous system; 
    GI: gastrointestinal; 
    XLR: X-linked recessive; 
    DNA: deoxyribonucleic acid; 
    AD: autosomal dominant; 
    GOF: gain of function; 
    MDS: myelodysplastic syndrome; 
    XL: X linked; 
    RNA: ribonucleic acid.</div><div class="graphic_reference">From: Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473. Copyright © 2022 The Authors. Reproduced under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License 4.0</a>.</div><div id="graphicVersion">Graphic 140092 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
